Ganirelix

Ganirelix Uses, Dosage, Side Effects, Food Interaction and all others data.

Ganirelix is an injectable competitive gonadotropin-releasing hormone antagonist (GnRH antagonist). It is utilized frequently in assisted reproduction therapy to control the occurrence of ovulation. The drug exerts its effects by inhibiting the action of GnRH in the pituitary gland, leading to fast suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Ganirelix is used in fertility treatment to prevent premature ovulation that could result in the harvesting of eggs that are too immature to be used in procedures such as in vitro fertilization. Ganirelix is marketed by Merck & Co., Inc. as Orgalutran®.

Ganirelix
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Ganirelix
Availability	Prescription only
Generic	Ganirelix
Ganirelix Other Names	Ganirelix
Related Drugs	Sprintec, Estarylla, ethinyl estradiol / norethindrone, Ortho Tri-Cyclen, Tri-Sprintec
Weight	250mcg/0.5ml,
Type	Subcutaneous Solution, Subcutaneous
Formula	C₈₀H₁₁₃ClN₁₈O₁₃
Weight	Average: 1570.35 Monoisotopic: 1568.8423035
Protein binding	81.9%.
Groups	Approved
Therapeutic Class
Manufacturer
Available Country	United States
Last Updated:	September 19, 2023 at 7:00 am

Uses

Ganirelix is a GnRH antagonist used in assisted reproduction in women undergoing controlled ovarian hyperstimulation to control ovulation by inhibiting the premature LH surges.

For the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.

Ganirelix is also used to associated treatment for these conditions: Controlled ovarian hyperstimulation therapy

How Ganirelix works

Ganirelix acts by competitively blocking the GnRH receptors on the pituitary gonadotroph and subsequent transduction pathway. It induces a rapid, reversible suppression of gonadotropin secretion. The suppression of pituitary LH secretion by ganirelix is more pronounced than that of FSH. An initial release of endogenous gonadotropins has not been detected with ganirelix, which is consistent with an antagonist effect. Upon discontinuation of ganirelix, pituitary LH and FSH levels are fully recovered within 48 hours.

Food Interaction

No interactions found.

Ganirelix Drug Interaction

Moderate: hcg

Ganirelix Disease Interaction

Major: severe allergiesModerate: renal/hepatic impairment

Volume of Distribution

The mean (SD) volume of distribution of Ganirelix in healthy females following intravenous administration of a single 250 mg dose is 43.7 (11.4) L.

Elimination Route

Ganirelix is rapidly absorbed following subcutaneous injection with maximum serum concentrations reached approximately one hour after dosing.

Half Life

16.2 hours.

Clearance

Single dose: 2.4L/hour Multiple dose: 3.3L/hour

Elimination Route

On average, 97.2% of the total radiolabeled ganirelix dose is recovered in the feces and urine (75.1% and 22.1%, respectively) over 288 h following intravenous single dose administration of 1 mg [14 75 C]-ganirelix acetate. Urinary excretion is virtually complete in 24 h, whereas fecal excretion starts to plateau 192 h after dosing.